NCT00140556 - Angiogenic and EGFR Blockade With Curative Chemoradiation for Advanced Head and Neck Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

May 31, 2009

Study Completion Date

April 30, 2010

Conditions

Head and Neck CancerPharynx Cancer

Interventions

RADIATION

Chemoradiotherapy

External beam radiation daily (M-F)

DRUG

Cisplatin

Cisplatin week 1 and 5 of radiation

DRUG

Bevacizumab

Bevacizumab (Avastin) day 1 of weeks 1, 3, and 5 of radiation

DRUG

Erlotinib

Erlotinib daily during radiation

Trial Locations (1)

Department of Radiation Oncology; Duke University Medical Center, Durham